{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:18:00Z","timestamp":1787876280935,"version":"build-2784847793"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P01-AI165075"],"award-info":[{"award-number":["P01-AI165075"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Townsend-Jeantet Charitable Trust"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The COVID-19 pandemic has demonstrated the detrimental potential of zoonotic coronavirus transmission to human populations. Effective vaccines capable of eliciting immunity to SARS-CoV-2 have been pivotal in mitigating the spread of the virus. In this study, we describe the generation of a non-replicating pseudotyped influenza A virus (S-FLU), where the native haemagglutinin (HA) sequence is replaced with the coding sequence of either a membrane-anchored form (TM) or secretory form (Sec) of the receptor-binding domain (RBD) of the ancestral SARS-CoV-2 Wuhan (S-RBD Wuhan). We showed that both S-RBD-TM and S-RBD-Sec viruses can be generated via reverse genetics and grown to high titre. Intranasal immunisation in mice with S-RBD-TM elicits robust serum binding and neutralisation activity against SARS-CoV-2, superior to S-RBD-Sec. Furthermore, we demonstrate that a heterologous prime-boost immunisation regimen in mice with S-RBD-TM Wuhan and S-RBD-TM BM48-31 (a distant Clade 3 SARS-like betacoronavirus (sarbecovirus)) increases antibody binding breadth against mismatched sarbecoviruses compared to homologous prime-boost with S-RBD-TM Wuhan, although this did not translate into significantly enhanced cross-neutralisation across the tested virus panel. These results demonstrate that S-RBD delivery via the intranasal route induces both systemic and mucosal antibody responses and provide a foundation for further optimisation of S-RBD sarbecovirus vaccine strategies.<\/jats:p>","DOI":"10.1038\/s41598-026-55581-y","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T15:54:21Z","timestamp":1781366061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a recombinant single-cycle influenza viral vector as an intranasal vaccine against SARS-CoV-2"],"prefix":"10.1038","volume":"16","author":[{"given":"Jonathan","family":"Munro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Melnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeeha","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Schimanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Keeffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Bjorkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain R.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiong Kit","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"issue":"7803","key":"55581_CR1","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1038\/s41586-020-2202-3","volume":"580","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. Author correction: A new coronavirus associated with human respiratory disease in China. Nature 580(7803), E7 (2020).","journal-title":"Nature"},{"issue":"7836","key":"55581_CR2","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1038\/s41586-020-2951-z","volume":"588","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 588(7836), E6 (2020).","journal-title":"Nature"},{"issue":"10359","key":"55581_CR3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S0140-6736(22)01585-9","volume":"400","author":"JD Sachs","year":"2022","unstructured":"Sachs, J. D. et al. The Lancet Commission on lessons for the future from the COVID-19 pandemic. Lancet 400(10359), 1224\u20131280 (2022).","journal-title":"Lancet"},{"issue":"7898","key":"55581_CR4","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","volume":"602","author":"JM Carreno","year":"2022","unstructured":"Carreno, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602(7898), 682\u2013688 (2022).","journal-title":"Nature"},{"issue":"13","key":"55581_CR5","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1016\/j.cell.2021.04.025","volume":"184","author":"X Deng","year":"2021","unstructured":"Deng, X. et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184(13), 3426-3437 e8 (2021).","journal-title":"Cell"},{"key":"55581_CR6","unstructured":"Liu, C., et al., Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 2021."},{"issue":"7854","key":"55581_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","volume":"592","author":"H Tegally","year":"2021","unstructured":"Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592(7854), 438\u2013443 (2021).","journal-title":"Nature"},{"key":"55581_CR8","unstructured":"Volz, E., et al., Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 In England. Nature, 2021."},{"key":"55581_CR9","unstructured":"Collier, D.A., et al., Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 2022. 608(7922): p. E24."},{"issue":"5","key":"55581_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMc2207519","volume":"387","author":"E Takashita","year":"2022","unstructured":"Takashita, E. et al. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N. Engl. J. Med. 387(5), 468\u2013470 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"7857","key":"55581_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593(7857), 130\u2013135 (2021).","journal-title":"Nature"},{"key":"55581_CR12","doi-asserted-by":"crossref","unstructured":"Wibmer, C.K., et al., SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med., (2021).","DOI":"10.1101\/2021.01.18.427166"},{"issue":"3","key":"55581_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17(3), 181\u2013192 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"55581_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev-micro-020518-115759","volume":"73","author":"TS Fung","year":"2019","unstructured":"Fung, T. S. & Liu, D. X. Human coronavirus: Host-pathogen interaction. Annu. Rev. Microbiol. 73, 529\u2013557 (2019).","journal-title":"Annu. Rev. Microbiol."},{"issue":"5748","key":"55581_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1126\/science.1118391","volume":"310","author":"W Li","year":"2005","unstructured":"Li, W. et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310(5748), 676\u2013679 (2005).","journal-title":"Science"},{"issue":"6268","key":"55581_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1126\/science.aac8608","volume":"351","author":"JS Sabir","year":"2016","unstructured":"Sabir, J. S. et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 351(6268), 81\u201384 (2016).","journal-title":"Science"},{"issue":"9393","key":"55581_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","volume":"362","author":"NS Zhong","year":"2003","unstructured":"Zhong, N. S. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February, 2003. Lancet 362(9393), 1353\u20131358 (2003).","journal-title":"Lancet"},{"issue":"20","key":"55581_CR18","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"C Drosten","year":"2003","unstructured":"Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20), 1967\u20131976 (2003).","journal-title":"N Engl J Med"},{"issue":"9371","key":"55581_CR19","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(03)13413-7","volume":"361","author":"JM Nicholls","year":"2003","unstructured":"Nicholls, J. M. et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 361(9371), 1773\u20131778 (2003).","journal-title":"Lancet"},{"issue":"19","key":"55581_CR20","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki, A. M. et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367(19), 1814\u20131820 (2012).","journal-title":"N. Engl. J. Med."},{"key":"55581_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2021.102026","volume":"41","author":"A Elhazmi","year":"2021","unstructured":"Elhazmi, A. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) coinfection: A unique case series. Travel Med. Infect. Dis. 41, 102026 (2021).","journal-title":"Travel Med. Infect. Dis."},{"key":"55581_CR22","doi-asserted-by":"crossref","unstructured":"van Boheemen, S., et al., Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio, 2012.","DOI":"10.1128\/mBio.00473-12"},{"key":"55581_CR23","doi-asserted-by":"crossref","unstructured":"Ge, X.Y., et al., Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature, (2013).","DOI":"10.1038\/nature12711"},{"key":"55581_CR24","doi-asserted-by":"crossref","unstructured":"Anthony, S.J., et al., Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus. Mbio, (2017).","DOI":"10.1128\/mBio.00373-17"},{"issue":"4","key":"55581_CR25","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5(4), 562 (2020).","journal-title":"Nat. Microbiol."},{"issue":"11","key":"55581_CR26","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1073\/pnas.1517719113","volume":"113","author":"VD Menachery","year":"2016","unstructured":"Menachery, V. D. et al. SARS-like WIV1-CoV poised for human emergence. Proc. Natl. Acad. Sci. U. S. A. 113(11), 3048\u20133053 (2016).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"55581_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12250-018-0012-7","volume":"33","author":"N Wang","year":"2018","unstructured":"Wang, N. et al. Serological evidence of bat SARS-related coronavirus infection in humans, China. Virol. Sin. 33(1), 104\u2013107 (2018).","journal-title":"Virol. Sin."},{"issue":"13","key":"55581_CR28","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.vaccine.2023.02.032","volume":"41","author":"KA Moore","year":"2023","unstructured":"Moore, K. A. et al. A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy. Vaccine 41(13), 2101\u20132112 (2023).","journal-title":"Vaccine"},{"issue":"1","key":"55581_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41541-022-00597-4","volume":"7","author":"F Zhao","year":"2022","unstructured":"Zhao, F. et al. Challenges and developments in universal vaccine design against SARS-CoV-2 variants. npj Vaccines 7(1), 167 (2022).","journal-title":"npj Vaccines"},{"issue":"6","key":"55581_CR30","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 183(6), 1735 (2020).","journal-title":"Cell"},{"key":"55581_CR31","doi-asserted-by":"crossref","unstructured":"Tortorici, M.A. and D. Veesler, Structural insights into coronavirus entry. Complementary Strategies to Understand Virus Structure and Function, 105: p. 93-116. (2019).","DOI":"10.1016\/bs.aivir.2019.08.002"},{"issue":"6504","key":"55581_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369(6504), 643\u2013650 (2020).","journal-title":"Science"},{"issue":"12","key":"55581_CR33","doi-asserted-by":"publisher","first-page":"e1010148","DOI":"10.1371\/journal.ppat.1010148","volume":"17","author":"KA Huang","year":"2021","unstructured":"Huang, K. A. et al. Correction: Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathog. 17(12), e1010148 (2021).","journal-title":"PLoS Pathog."},{"issue":"7821","key":"55581_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584(7821), 450\u2013456 (2020).","journal-title":"Nature"},{"issue":"7821","key":"55581_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584(7821), 437\u2013442 (2020).","journal-title":"Nature"},{"issue":"7839","key":"55581_CR36","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588(7839), 682\u2013687 (2020).","journal-title":"Nature"},{"issue":"1","key":"55581_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41467-023-35949-8","volume":"14","author":"KA Huang","year":"2023","unstructured":"Huang, K. A. et al. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2. Nat. Commun. 14(1), 311 (2023).","journal-title":"Nat. Commun."},{"issue":"7815","key":"55581_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583(7815), 290\u2013295 (2020).","journal-title":"Nature"},{"issue":"7874","key":"55581_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41586-021-03817-4","volume":"597","author":"MA Tortorici","year":"2021","unstructured":"Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 597(7874), 103\u2013108 (2021).","journal-title":"Nature"},{"issue":"6504","key":"55581_CR40","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369(6504), 731\u2013736 (2020).","journal-title":"Science"},{"issue":"12","key":"55581_CR41","doi-asserted-by":"publisher","first-page":"110188","DOI":"10.1016\/j.celrep.2021.110188","volume":"37","author":"CA Jette","year":"2021","unstructured":"Jette, C. A. et al. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Rep. 37(12), 110188 (2021).","journal-title":"Cell Rep."},{"issue":"7","key":"55581_CR42","doi-asserted-by":"publisher","first-page":"e0159622","DOI":"10.1128\/jvi.01596-22","volume":"97","author":"JL Jensen","year":"2023","unstructured":"Jensen, J. L. et al. Targeting the spike receptor binding domain class V cryptic epitope by an antibody with Pan-Sarbecovirus activity. J. Virol. 97(7), e0159622 (2023).","journal-title":"J. Virol."},{"issue":"7","key":"55581_CR43","doi-asserted-by":"publisher","first-page":"110208","DOI":"10.1016\/j.isci.2024.110208","volume":"27","author":"L Cui","year":"2024","unstructured":"Cui, L. et al. A cryptic site in class 5 epitope of SARS-CoV-2 RBD maintains highly conservation across natural isolates. iScience 27(7), 110208 (2024).","journal-title":"iScience"},{"issue":"3","key":"55581_CR44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1099\/jgv.0.001228","volume":"100","author":"TJ Powell","year":"2019","unstructured":"Powell, T. J. et al. A single cycle influenza virus coated in H7 haemagglutinin generates neutralizing antibody responses to haemagglutinin and neuraminidase glycoproteins and protection from heterotypic challenge. J. Gen. Virol. 100(3), 431\u2013445 (2019).","journal-title":"J. Gen. Virol."},{"issue":"24","key":"55581_CR45","doi-asserted-by":"publisher","first-page":"13397","DOI":"10.1128\/JVI.01820-12","volume":"86","author":"TJ Powell","year":"2012","unstructured":"Powell, T. J. et al. Pseudotyped Influenza A Virus as a vaccine for the induction of heterotypic immunity. J. Virol. 86(24), 13397\u201313406 (2012).","journal-title":"J. Virol."},{"issue":"1","key":"55581_CR46","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1038\/s41467-023-37697-1","volume":"14","author":"S Deng","year":"2023","unstructured":"Deng, S. et al. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. Nat Commun 14(1), 2081 (2023).","journal-title":"Nat Commun"},{"key":"55581_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/v12090987","author":"AN Loes","year":"2020","unstructured":"Loes, A. N. et al. Attenuated Influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice. Viruses https:\/\/doi.org\/10.3390\/v12090987 (2020).","journal-title":"Viruses"},{"key":"55581_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11061063","author":"MJ Moser","year":"2023","unstructured":"Moser, M. J. et al. Intranasal single-replication Influenza vector induces cross-reactive serum and mucosal antibodies against SARS-CoV-2 variants. Vaccines https:\/\/doi.org\/10.3390\/vaccines11061063 (2023).","journal-title":"Vaccines"},{"key":"55581_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2022.109491","volume":"271","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. An influenza virus vector candidate vaccine stably expressing SARS-CoV-2 receptor-binding domain produces high and long-lasting neutralizing antibodies in mice. Vet. Microbiol. 271, 109491 (2022).","journal-title":"Vet. Microbiol."},{"issue":"1","key":"55581_CR50","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"X Ou","year":"2020","unstructured":"Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11(1), 1620 (2020).","journal-title":"Nat. Commun."},{"key":"55581_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00941-17","author":"JH Xiao","year":"2018","unstructured":"Xiao, J. H. et al. Characterization of Influenza virus pseudotyped with Ebolavirus glycoprotein. J. Virol. https:\/\/doi.org\/10.1128\/JVI.00941-17 (2018).","journal-title":"J. Virol."},{"key":"55581_CR52","doi-asserted-by":"publisher","first-page":"1608074","DOI":"10.3389\/fimmu.2025.1608074","volume":"16","author":"TK Tan","year":"2025","unstructured":"Tan, T. K. et al. Single-cycle, pseudotyped reporter influenza virus to facilitate evaluation of treatment strategies for avian influenza, Ebola and other highly infectious diseases in vivo. Front Immunol 16, 1608074 (2025).","journal-title":"Front Immunol"},{"issue":"3","key":"55581_CR53","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","volume":"166","author":"NL Kallewaard","year":"2016","unstructured":"Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing all Influenza A subtypes. Cell 166(3), 596\u2013608 (2016).","journal-title":"Cell"},{"issue":"1","key":"55581_CR54","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41467-020-20654-7","volume":"12","author":"TK Tan","year":"2021","unstructured":"Tan, T. K. et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat Commun 12(1), 542 (2021).","journal-title":"Nat Commun"},{"key":"55581_CR55","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.omtn.2023.01.008","volume":"31","author":"AD Gelinas","year":"2023","unstructured":"Gelinas, A. D. et al. Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents. Mol. Ther. Nucleic Acids 31, 370\u2013382 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"55581_CR56","doi-asserted-by":"crossref","unstructured":"Afzal, M., et al., Determination of resilience of a panel of broadly neutralizing mAbs to emerging variants of SARS-CoV-2 generated using reverse genetics. iScience, 28(6): p. 112451. (2025).","DOI":"10.1016\/j.isci.2025.112451"},{"key":"55581_CR57","doi-asserted-by":"crossref","unstructured":"Van Reeth, K., et al., Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection. NPJ Vaccines, (2017).","DOI":"10.1038\/s41541-017-0012-x"},{"key":"55581_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11071209","author":"N Bhatnagar","year":"2023","unstructured":"Bhatnagar, N. et al. Heterologous prime-boost vaccination with inactivated Influenza viruses induces more effective cross-protection than homologous repeat vaccination. Vaccines https:\/\/doi.org\/10.3390\/vaccines11071209 (2023).","journal-title":"Vaccines"},{"key":"55581_CR59","doi-asserted-by":"publisher","first-page":"1142394","DOI":"10.3389\/fimmu.2023.1142394","volume":"14","author":"X Li","year":"2023","unstructured":"Li, X. et al. Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice. Front. Immunol. 14, 1142394 (2023).","journal-title":"Front. Immunol."},{"key":"55581_CR60","doi-asserted-by":"crossref","unstructured":"Cohen, A.A., et al., Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science, 377(6606): p. eabq0839. (2022).","DOI":"10.1126\/science.abq0839"},{"issue":"5","key":"55581_CR61","doi-asserted-by":"publisher","first-page":"e01487","DOI":"10.1128\/mBio.01487-15","volume":"6","author":"M Baz","year":"2015","unstructured":"Baz, M. et al. Nonreplicating Influenza A virus vaccines confer broad protection against lethal challenge. MBio 6(5), e01487-e1515 (2015).","journal-title":"MBio"},{"issue":"3","key":"55581_CR62","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4049\/jimmunol.2001086","volume":"206","author":"V Martini","year":"2021","unstructured":"Martini, V. et al. Simultaneous aerosol and intramuscular immunization with influenza vaccine induces powerful protective local T cell and systemic antibody immune responses in pigs. J. Immunol. 206(3), 652\u2013663 (2021).","journal-title":"J. Immunol."},{"key":"55581_CR63","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.76414","author":"M Kandasamy","year":"2023","unstructured":"Kandasamy, M. et al. Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors. Elife https:\/\/doi.org\/10.7554\/eLife.76414 (2023).","journal-title":"Elife"},{"issue":"6505","key":"55581_CR64","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369(6505), 806\u2013811 (2020).","journal-title":"Science"},{"issue":"10","key":"55581_CR65","doi-asserted-by":"publisher","first-page":"e1011670","DOI":"10.1371\/journal.ppat.1011670","volume":"19","author":"TL Chandler","year":"2023","unstructured":"Chandler, T. L. et al. Protective mechanisms of nonneutralizing antiviral antibodies. PLoS Pathog 19(10), e1011670 (2023).","journal-title":"PLoS Pathog"},{"issue":"6","key":"55581_CR66","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","volume":"23","author":"A Zhang","year":"2023","unstructured":"Zhang, A. et al. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat. Rev. Immunol. 23(6), 381\u2013396 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"55581_CR67","doi-asserted-by":"publisher","first-page":"102278","DOI":"10.1016\/j.coi.2022.102278","volume":"80","author":"J Tang","year":"2023","unstructured":"Tang, J. & Sun, J. Lung tissue-resident memory T cells: The gatekeeper to respiratory viral (re)-infection. Curr. Opin. Immunol. 80, 102278 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"55581_CR68","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.184074","author":"A Odle","year":"2024","unstructured":"Odle, A. et al. Tissue-resident memory T cells contribute to protection against heterologous SARS-CoV-2 challenge. JCI. Insight https:\/\/doi.org\/10.1172\/jci.insight.184074 (2024).","journal-title":"JCI. Insight"},{"issue":"10","key":"55581_CR69","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41594-020-0480-y","volume":"27","author":"D Zhou","year":"2020","unstructured":"Zhou, D. et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat. Struct. Mol. Biol. 27(10), 950\u2013958 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6510","key":"55581_CR70","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369(6510), 1501\u20131505 (2020).","journal-title":"Science"},{"key":"55581_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/v12050513","author":"KHD Crawford","year":"2020","unstructured":"Crawford, K. H. D. et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike Protein for neutralization assays. Viruses https:\/\/doi.org\/10.3390\/v12050513 (2020).","journal-title":"Viruses"},{"issue":"26","key":"55581_CR72","doi-asserted-by":"publisher","first-page":"10598","DOI":"10.1073\/pnas.1309215110","volume":"110","author":"AP West Jr.","year":"2013","unstructured":"West, A. P. Jr. et al. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc. Natl. Acad. Sci. U. S. A. 110(26), 10598\u201310603 (2013).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"55581_CR73","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.1016\/j.cell.2024.07.052","volume":"187","author":"AA Cohen","year":"2024","unstructured":"Cohen, A. A. et al. Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals. Cell 187(20), 5554-5571 e19 (2024).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55581-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:49:54Z","timestamp":1787874594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55581-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55581"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55581-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27047"}}